Rankings
▼
Calendar
FATE Q3 2025 Earnings — Fate Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
FATE
Fate Therapeutics, Inc.
$158M
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-43.4% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$35M
-1995.1% margin
Net Income
-$32M
-1852.4% margin
EPS (Diluted)
$-0.27
QoQ Revenue Growth
-8.7%
Cash Flow
Operating Cash Flow
-$24M
Free Cash Flow
-$27M
Stock-Based Comp.
$5M
Balance Sheet
Total Assets
$344M
Total Liabilities
$110M
Stockholders' Equity
$234M
Cash & Equivalents
$41M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$3M
-43.4%
Gross Profit
$2M
$3M
-43.4%
Operating Income
-$35M
-$52M
+33.7%
Net Income
-$32M
-$48M
+32.4%
← FY 2025
All Quarters
Q4 2025 →